A novel approach to assessing the drug susceptibility and replication of human immunodeficiency virus type 1 isolates

Journal of Infectious Diseases

Volumn 175, Issue 3, 1997, Pages 561-566

  Jellinger, Robert M ^a   Shafer, Robert W ^a,b   Merigan, Thomas C ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; LAMIVUDINE; NEVIRAPINE; ZIDOVUDINE;

ARTICLE; CONCENTRATION RESPONSE; CYTOPATHOGENIC EFFECT; DRUG SCREENING; DRUG SENSITIVITY; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; VIRUS CULTURE; VIRUS ISOLATION; VIRUS MUTATION; VIRUS REPLICATION;

EID: 0031016173     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/175.3.561     Document Type: Article

References (22)

1. Richman DD. Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993;37: 1207-13.
2. Erice A, Balfour HH Jr. Resistance of human immunodeficiency virus type 1 to antiretroviral agents: a review. Clin Infect Dis 1994;18: 149-56.
3. Shafer RW, Merigan TC. HIV virology for clinical trials. AIDS 1995; 9(suppl A):S193-202.
4. Pauwels R, Balzarini J, Baba M, et al. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988;20:309-21.
5. Weislow OS, Kiser R, Fine DL, Bader J, Shoemaker RH, Boyd MR. New soluble formazan assay for HIV-1 cytopathic effects: application to high-flux screening of synthetic and natural products for AIDS-antiviral activity. J Natl Cancer Inst 1989;81:577-86.
6. Iversen AKN, Shafer RW, Wehrly K, et al. Multidrug-resistant HIV-1 resulting from combination antiretroviral therapy. J Virol 1996;70: 1076-80.
7. Kellam P, Larder BA. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother 1994;38:23-30.
8. Boucher CAB, Keulen W, von Bommel T, et al. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother 1996;40:2404-9.
9. Schmidt NJ. Cell culture procedures for diagnostic virology. In: Schmidt NJ, Emmons RW, eds. Diagnostic procedures for viral, rickettsial, and chlamydial infections. Washington, DC: American Public Health Association, 1989:78-9.
10. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
11. Nijhuis M, Boucher CAB, Schuurman R. Sensitive procedure for the amplification of HIV-1 RNA using a combined reverse-transcription and amplification reaction. Biotechniques 1995;19:178-82.
12. Larder BA, Chesebro B, Richman DD. Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother 1990;34:436-41.
13. Japour AJ, Mayers DL, Johnson VA, et al. Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother 1993;37: 1095-101.
14. Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992; 89:1934-8.
15. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269:696-9.
16. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994;68:1660-6.
17. Sandström E, Öberg B. Antiviral therapy in human immunodeficiency virus infections: current status. I. Drugs 1993;45:488-508.
18. van Leeuwen R, Katlama C, Kitchen V, et al. Evaluation and safety of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study. J Infect Dis 1995;171:1166-71.
19. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995;171:537-45.
20. Harrigan PR, Kingdom I, Bloor S, et al. Significance of amino acid variation at human immunodeficiency virus type I reverse transcriptase residue 210 for zidovudine susceptibility. J Virol 1996;5930-4.
21. Tisdale M, Myers RE, Maschera B, Parry NR, Oliver NM, Blair ED. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob Agents Chemother 1995;39:1704-10.
22. Larder BA, Kohli A, Bloor S, et al. Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2′,3′-dideoxyinosine or AZT plus 2′,3′-dideoxyeytidine combination therapy. J Virol 1996;70:5922-9.